Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Characterizing cognitive function during relapse in multiple sclerosis.

Ralph Hb Benedict1, Sarah Morrow2, Jonathan Rodgers3

  • 1Buffalo General Hospital, Suite E2, 100 High Street, Buffalo, New York, 14203, USA benedict@buffalo.edu.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|May 21, 2014
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Relating perivascular imaging measures to longitudinal lesion evolution and chronic inflammation in multiple sclerosis.

Multiple sclerosis and related disorders·2026
Same author

Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.

Journal of neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal of neurology·2026
Same author

Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.

Journal of neurology·2026
Same journal

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles
This summary is machine-generated.

Cognitive function in multiple sclerosis (MS) patients significantly declines during relapse, as measured by neuropsychological (NP) testing. This impairment resolves by three months post-relapse, indicating a temporary impact of relapse on MS cognition.

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Cognitive Science

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease affecting cognitive function.
  • Cognitive symptoms are common in MS patients, impacting daily life.
  • Understanding cognitive changes during MS relapse is crucial for patient management.

Purpose of the Study:

  • To evaluate neuropsychological (NP) test performance in patients experiencing a multiple sclerosis (MS) relapse.
  • To compare cognitive function during relapse and recovery against stable controls.
  • To correlate NP changes with clinical and imaging markers of relapse.

Main Methods:

  • NP testing and Expanded Disability Status Scale (EDSS) were administered to 24 relapsing MS patients and 24 matched controls.
Keywords:
Multiple sclerosisoutcome measurementrelapsing–remitting

Related Experiment Videos

  • Patients with cognitive symptoms but without factors compromising NP testing were included.
  • Enhancing MRI lesions confirmed relapse; corticosteroid treatment was administered. Comparisons were made to pre-relapse baseline and 3-month follow-up.

    • Main Results:

    • A significant decline in Symbol Digit Modalities Test (SDMT) scores (p=0.005) and worsening EDSS (p=0.019) were observed during relapse.
    • Cognitive impairment was evident in relapsing patients but not in controls.
    • Differences between groups resolved by the three-month follow-up, with SDMT decline averaging 6%.

    Conclusions:

    • This study provides the first assessment of NP status changes during MS relapse using validated metrics.
    • Decline in NP testing, reported cognitive changes, and MRI lesions confirm a clinically significant event during relapse.
    • Cognitive function during MS relapse is demonstrably impaired but recovers over time.